The University of Pittsburgh has received a USD 2.16 million NIAID P01 program grant to establish the Pitt Center for Accelerating Phage Therapy (P-CAPT), a multi-project initiative targeting multidrug-resistant Pseudomonas aeruginosa — one of the most treatment-resistant bacterial pathogens in clinical medicine. The award, issued in April 2026 and running through March 2031, positions Pittsburgh as a coordinating hub for an academic-government-industry consortium working to move phage therapy closer to routine clinical use.
Consortium structure and research scope
The P-CAPT program, led by Daria Van Tyne at the University of Pittsburgh, draws together investigators from the University of Southern California, the Walter Reed Army Institute of Research, and Intralytix, a commercial phage development company. The P01 mechanism — a coordinated program project format — supports two research projects and two scientific cores. Research Project 1 focuses on developing standardized assays and tools to optimize phage cocktail design. Research Project 2 applies systems-based pharmacokinetic and pharmacodynamic modeling to establish dosing protocols. A dedicated Phage Core will manage development, analysis, and current good manufacturing practice (cGMP) production across the entire program, while an Animal Core will conduct in vivo testing in established mouse models of P. aeruginosa respiratory infection.
MDR P. aeruginosa causes severe pneumonia and bacteremia, particularly in immunocompromised patients and those with cystic fibrosis or prolonged hospital stays. The pathogen's capacity to acquire resistance through multiple mechanisms — including efflux pumps, porin loss, and beta-lactamase production — has progressively narrowed the antibiotic options available to clinicians. Phage therapy, which uses bacteriophages to selectively lyse bacterial targets, has attracted renewed research interest as antibiotic pipelines for gram-negative pathogens have thinned. The P-CAPT program draws on biospecimens collected from patients who previously received phage therapy under compassionate use protocols and in earlier clinical studies, giving the consortium access to translational data that purely laboratory-based programs lack.
The program's emphasis on cGMP manufacturing and PK/PD modeling reflects an effort to close the gap between experimental phage use and scalable, reproducible clinical deployment. Prior compassionate use cases, while informative, have generally involved individualized, one-off phage preparations that are difficult to standardize or replicate at scale. By building a manufacturing core and developing rigorous dosing frameworks, P-CAPT is designed to generate the kind of reproducible, quantitative data that regulatory agencies require before broader clinical adoption. The program also frames MDR P. aeruginosa as a model system for ESKAPE pathogens more broadly, suggesting that methods developed here could be applied to other high-priority drug-resistant organisms.